LupusNephritis: A Hidden Threat to Kidney Health | Genentech posted on the topic | LinkedIn

LinkedIn respects your privacy

LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.

Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.

View organization page for Genentech

850,007 followers

3d

#LupusNephritis is a serious and often underrecognized manifestation of lupus that can lead to lasting kidney damage. The challenge is that symptoms can be subtle or easily missed, leading to delays in diagnosis when time matters the most. Earlier recognition can make a significant difference in improving long-term outcomes for patients. We're working to advance education and awareness to help healthcare providers and patients recognize the signs sooner and make more informed care decisions.

2 Comments

Alliance for a Healthier South Carolina, graphic

Alliance for a Healthier South Carolina

3d

Education is key, the more providers and patients know, the better the outcomes.

Alexander Marakhovsky, MD, MBA, graphic

Alexander Marakhovsky, MD, MBA

Business development manager. Human health, Pharmaceuticals.

3d

Despite of relatively low incidence it is a serious risk of kidney failure and overall number of patients is huge with tendency to grow.

See more comments

To view or add a comment, sign in

More Relevant Posts

Rosa Mañoso Guardia

Talent Acquisition Partner | R&D Recruitment @ AstraZeneca / Alexion
1mo
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in
Jason Wright, Pharm.D.

Senior Global Medical Affairs Leader at AstraZeneca
1mo
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in
Suzanne Bellomo

Global Talent Scout at AstraZeneca
1mo
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in
Alexandra Peñaloza Muñoz

Employer Brand & Recruitment Marketing Manager
1mo
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in
Georgina H.

Global Talent Acquisition Partner, Commercial at AstraZeneca Pharmaceuticals. Passionate about connecting great talent with incredible opportunities!
1mo
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in
Alexandra Gunn

Global Senior Talent Acquisition Partner at AstraZeneca
4w
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
1 Comment
Like Comment
To view or add a comment, sign in
Aletse Ortiz Gomez

TAq Partner - AstraZeneca
3w
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in
Suffwan Eltom

Chief of Staff, BioPharmaceuticals Business Unit @ AstraZeneca
3w
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in
Alejandra Diaz

Talent Acquisition | IT Recruitment | People Manager
3w
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in
Karen Chau CHRP

Global Talent Acquisition Partner at AstraZeneca
3w
Report this post
I’m proud to be part of an organisation that is addressing the challenges in improving timely and accurate diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is often overlooked and misunderstood. Early detection and diagnosis are critical to improving health outcomes for patients with this rapidly progressive and potentially fatal disease, yet up to 32% of patients with ATTR-CM report seeing six or more doctors before receiving an accurate diagnosis. Learn more about how @AstraZeneca [TAG] is advancing earlier diagnosis and detection for amyloidosis for patients around the world: https://bit.ly/4n6UDgx #ESCCongress
Like Comment
To view or add a comment, sign in

Genentech

850,007 followers

View Profile Follow

More from this author

Explore content categories